Table 3 Incremental cost per quality-adjusted life year (QALY) gained by vaccination for vaccine uptake rate 50% increase scenario.
From: An economic and disease transmission model of human papillomavirus and oropharyngeal cancer in Texas
Coverage strategy | Total cost* | Lost-QALYs | Incremental cost | Lost-QALYs difference | $/QALY |
|---|---|---|---|---|---|
Base case vaccine cost: $178.14; intervention cost: $50.64 for the first dose; $20.26 for the second dose | |||||
Baseline | $6,865,857,562 | 1,281,115 | |||
50% increase over current rate for females | $13,531,356,911 | 1,228,503 | $6,665,499,349 | 52,612 | $126,689.20 |
50% increase over current rate for males and females | $20,219,433,083 | 1,157,743 | $6,688,076,172 | 70,760 | $94,517.75 |
Best case vaccine cost: $142.512; intervention cost: $20.26 for the first dose; $20.26 for the second dose | |||||
Baseline | $6,082,500,600 | 1,281,115 | |||
50% increase females | $9,856,665,333 | 1,228,503 | $3,774,164,732 | 52,612 | $71,734.45 |
50% increase males and females | $13,657,816,653 | 1,157,743 | $3,801,151,321 | 70,760 | $53,718.93 |
Worst case vaccine cost: $217.11; intervention cost: $87.92 for the first dose; $20.26 for the second dose | |||||
Baseline | $7,722,695,466 | 1,281,115 | |||
50% increase females | $17,933,089,043 | 1,228,503 | $10,210,393,577 | 52,612 | $194,065.98 |
50% increase males and females | $28,157,746,183 | 1,157,743 | $10,224,657,141 | 70,760 | $144,497.70 |
